Navigation Links
WARF signs license agreement with Pfizer for human embryonic stem cells

MADISON Pfizer Inc., a major biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, nonprofit patenting and licensing organization for the University of Wisconsin-Madison, announced May 5 that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies.

The WARF license provides Pfizer the rights to work with hES cells for drug research and discovery. Securing appropriate licenses, in an area as broad and rapidly moving as regenerative medicine, helps ensure rapid and efficient utilization of the many existing discoveries and inventions in this field and allows for the efficient transfer of information for development of future inventions.

"Our license with WARF provides us with information and materials that will allow us to use their cell lines to explore a whole new range of therapies," says Ruth McKernan, chief scientific officer of Pfizer Regenerative Medicine. "Stem cells can be used to create specialized human tissue. Our scientists will determine how new medicines may be able to improve the way stem cells regenerate damaged tissues. We will be optimizing the production of cells that could, one day, be used for therapeutic purposes."

"Pfizer's stem-cell R&D goal is three fold: to use human cells as tools in our drug discovery efforts, to improve the safety of new treatments and, most importantly, to move towards cell therapy," says McKernan. "The benefit to public health could be tremendous as we pursue our discoveries to advance the treatment of debilitating diseases."

"We are pleased to enter into this licensing agreement with Pfizer," said Carl E. Gulbrandsen, managing director of WARF. "Pfizer's access to this key intellectual property may have far-reaching benefits for both public health and Wisconsin's growing biotechnology industry."

As advances in health care help people live longer, the need for new medicines to keep people healthy continues to grow. Pfizer researchers and scientists are working to discover and develop new ways to treat and prevent life-threatening and debilitating illnesses, as well as to improve wellness and quality of life.

In November, Pfizer launched the Pfizer Regenerative Medicine research unit. This independent research organization will build on Pfizer's years of experience in this field and recent progress in understanding the biology of hES cells. Stem cells provide an opportunity to discover and develop a new generation of medicines for major medical needs. Pfizer's initial research in this area focused on the development of drug discovery tools and now expands into developing regenerative medicines that could benefit millions of patients worldwide.


Contact: Janet Kelly
University of Wisconsin-Madison

Related biology news :

1. Unifying the animate and the inanimate designs of nature
2. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
3. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
4. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
5. Engineering technology pinpoints earliest signs of animal life
6. University of Miami engineer designs stretchable electronics with a twist
7. bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC
8. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
9. Great Ape Trust signs agreement with Universitas Nasional in Jakarta
10. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... YORK , November 24, 2015 ... in a European healthcare ... which the companies will work closely together in identifying European ... unmet medical need. The collaboration is underpinned by a significant ... fund. This is the first investment by Bristol-Myers Squibb in ...
Breaking Biology Technology: